AQR Capital Management LLC Sells 105,155 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

AQR Capital Management LLC trimmed its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 463,163 shares of the biotechnology company's stock after selling 105,155 shares during the period. AQR Capital Management LLC owned 0.32% of Aurinia Pharmaceuticals worth $4,159,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Invesco Ltd. lifted its holdings in Aurinia Pharmaceuticals by 1.0% in the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock valued at $1,294,000 after acquiring an additional 1,421 shares during the last quarter. Teacher Retirement System of Texas raised its position in Aurinia Pharmaceuticals by 5.9% during the fourth quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock valued at $324,000 after buying an additional 2,020 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 2,635 shares during the period. SBI Securities Co. Ltd. purchased a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $25,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Aurinia Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock valued at $273,000 after buying an additional 2,857 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Greg Keenan sold 12,239 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This represents a 7.03% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 343,898 shares of company stock worth $2,753,094. Company insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Stock Performance

AUPH traded up $0.03 on Wednesday, hitting $7.85. The company had a trading volume of 2,097,506 shares, compared to its average volume of 1,340,328. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -52.33 and a beta of 1.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company's fifty day moving average price is $8.03 and its 200 day moving average price is $8.23. Aurinia Pharmaceuticals Inc. has a 1-year low of $5.08 and a 1-year high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. The business had revenue of $62.47 million during the quarter, compared to analysts' expectations of $61.06 million. Equities analysts predict that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.